Four strategies for oncology drug development in a post-COVID world
COVID-19 has changed every aspect of drug development. From novel endpoints to the advanced adoption of real-world evidence to decentralized trial designs, Parexel's experts and one insightful patient explore what new imperatives oncology drug developers can adopt to speed life-changing therapies to patients in need.
- Incorporating novel surrogate endpoints
- Leveraging external / synthetic control arms
- Patient insights for oncology trial design
- Benefits of demonstrating value earlier